Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Hoffman, Allison K.
2018.
Discrimination Risks of Alzheimer's as Support for Social Insurance for Long-Term Care.
Journal of Law, Medicine & Ethics,
Vol. 46,
Issue. 2,
p.
499.
Bonham, Luke W.
Sirkis, Daniel W.
Hess, Christopher P.
Sugrue, Leo P.
and
Yokoyama, Jennifer S.
2019.
The Radiogenomics of Late-onset Alzheimer Disease.
Topics in Magnetic Resonance Imaging,
Vol. 28,
Issue. 6,
p.
325.
Largent, Emily A.
2019.
Precision Medicine Research: An Exception or An Exemplar?.
Journal of Law, Medicine & Ethics,
Vol. 47,
Issue. 1,
p.
149.
Largent, Emily A.
Harkins, Kristin
van Dyck, Christopher H.
Hachey, Sara
Sankar, Pamela
Karlawish, Jason
and
Bouldin, Erin
2020.
Cognitively unimpaired adults’ reactions to disclosure of amyloid PET scan results.
PLOS ONE,
Vol. 15,
Issue. 2,
p.
e0229137.
Rostamzadeh, Ayda
Schwegler, Carolin
Gil-Navarro, Silvia
Rosende-Roca, Maitée
Romotzky, Vanessa
Ortega, Gemma
Canabate, Pilar
Moreno, Mariola
Schmitz-Luhn, Björn
Boada, Mercè
Jessen, Frank
and
Woopen, Christiane
2021.
Biomarker-Based Risk Prediction of Alzheimer’s Disease Dementia in Mild Cognitive Impairment: Psychosocial, Ethical, and Legal Aspects.
Journal of Alzheimer's Disease,
Vol. 80,
Issue. 2,
p.
601.
Tyler, Ana M.
Yokoyama, Jennifer S.
and
Arias, Jalayne J.
2021.
Personal Utility and Early Intervention in Alzheimer’s Disease.
AJOB Neuroscience,
Vol. 12,
Issue. 4,
p.
226.
Largent, Emily A.
Wexler, Anna
and
Karlawish, Jason
2021.
The Future Is P-Tau—Anticipating Direct-to-Consumer Alzheimer Disease Blood Tests.
JAMA Neurology,
Vol. 78,
Issue. 4,
p.
379.
Chiong, Winston
Tsou, Amy Y.
Simmons, Zachary
Bonnie, Richard J.
Russell, James A.
Busl, Katharina M.
Conwit, Robin A.
Cruz-Flores, Salvador
Epstein, Leon G.
Graf, William D.
Kirschen, Matthew
Kurek, Julie A.
Larriviere, Daniel G.
Lewis, Ariane
Sattin, Justin A.
Simpson, Ericka P.
Taylor, Lynne P.
and
Vernon, Laura
2021.
Ethical Considerations in Dementia Diagnosis and Care.
Neurology,
Vol. 97,
Issue. 2,
p.
80.
Rosen, Allyson C.
Arias, Jalayne J.
Ashford, J. Wesson
Blacker, Deborah
Chhatwal, Jasmeer P.
Chin, Nathan A.
Clark, Lindsay
Denny, Sharon S.
Goldman, Jill S.
Gleason, Carey E.
Grill, Joshua D.
Heidebrink, Judith L.
Henderson, Victor W.
Lavacot, James A.
Lingler, Jennifer H.
Menon, Malavika
Nosheny, Rachel L.
Oliveira, Fabricio F.
Parker, Monica W.
Rahman-Filipiak, Annalise
Revoori, Anwita
Rumbaugh, Malia C.
Sanchez, Danurys L.
Schindler, Suzanne E.
Schwarz, Christopher G.
Toy, Leslie
Tyrone, Jamie
Walter, Sarah
Wang, Li-san
Wijsman, Ellen M.
Zallen, Doris T.
and
Aggarwal, Neelum T.
2022.
The Advisory Group on Risk Evidence Education for Dementia: Multidisciplinary and Open to All.
Journal of Alzheimer's Disease,
Vol. 90,
Issue. 3,
p.
953.
Stites, Shana D.
Gill, Jeanine
Largent, Emily A.
Harkins, Kristin
Sankar, Pamela
Krieger, Abba
and
Karlawish, Jason
2022.
The relative contributions of biomarkers, disease modifying treatment, and dementia severity to Alzheimer's stigma: A vignette-based experiment.
Social Science & Medicine,
Vol. 292,
Issue. ,
p.
114620.
Gale, Seth A.
Heidebrink, Judith
Grill, Joshua
Graff-Radford, Jonathan
Jicha, Gregory A.
Menard, William
Nowrangi, Milap
Sami, Susie
Sirivong, Shirley
Walter, Sarah
and
Karlawish, Jason
2022.
Preclinical Alzheimer Disease and the Electronic Health Record.
Neurology,
Vol. 99,
Issue. 22,
p.
987.
Rosen, Allyson C.
2022.
Communicating and Using Dementia Risk Evidence.
Journal of Alzheimer's Disease,
Vol. 90,
Issue. 3,
p.
933.
Erickson, Claire M.
Clark, Lindsay R.
Ketchum, Fred B.
Chin, Nathaniel A.
Gleason, Carey E.
and
Largent, Emily A.
2022.
Implications of preclinical Alzheimer's disease biomarker disclosure for US policy and society.
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring,
Vol. 14,
Issue. 1,
Largent, Emily A.
Grill, Joshua D.
O'Brien, Kyra
Wolk, David
Harkins, Kristin
and
Karlawish, Jason
2023.
Testing for Alzheimer Disease Biomarkers and Disclosing Results Across the Disease Continuum.
Neurology,
Vol. 100,
Issue. 21,
p.
1010.
Chandra, Amitabh
Coile, Courtney
and
Mommaerts, Corina
2023.
What Can Economics Say about Alzheimer’s Disease?.
Journal of Economic Literature,
Vol. 61,
Issue. 2,
p.
428.
Lee, Joseph
2023.
Mild Cognitive Impairment in Relation to Alzheimer’s Disease: An Investigation of Principles, Classifications, Ethics, and Problems.
Neuroethics,
Vol. 16,
Issue. 2,
Russo, Federica
2023.
Integrative Approaches in Environmental Health and Exposome Research.
p.
35.
Vaishnav, Neil
Gonzalez, Rosa
Karunungan, Krystal
Tyler, Ana
Zheng, William
and
Arias, Jalayne J.
2024.
Creating an Unprotected Class: Addressing Legal Risks in the Era of Biologically-Defined Alzheimer’s Disease.
Journal of Alzheimer's Disease,
Vol. 98,
Issue. 1,
p.
187.
Mielke, Michelle M.
Anderson, Matthew
Ashford, J. Wesson
Jeromin, Andreas
Lin, Pei‐Jung
Rosen, Allyson
Tyrone, Jamie
VandeVrede, Lawren
Willis, Deanna
Hansson, Oskar
Khachaturian, Ara S.
Schindler, Suzanne E.
Weiss, Joan
Batrla, Richard
Bozeat, Sasha
Dwyer, John R.
Holzapfel, Drew
Jones, Daryl Rhys
Murray, James F.
Partrick, Katherine A.
Scholler, Emily
Vradenburg, George
Young, Dylan
Braunstein, Joel B.
Burnham, Samantha C.
de Oliveira, Fabricio Ferreira
Hu, Yan Helen
Mattke, Soeren
Merali, Zul
Monane, Mark
Sabbagh, Marwan Noel
Shobin, Eli
Weiner, Michael W.
and
Udeh‐Momoh, Chinedu T.
2024.
Considerations for widespread implementation of blood‐based biomarkers of Alzheimer's disease.
Alzheimer's & Dementia,
Vol. 20,
Issue. 11,
p.
8209.
Erickson, Claire
and
Largent, Emily A.
2024.
Digital Health Care outside of Traditional Clinical Settings.
p.
92.